ORGO Stock Analysis: Buy, Sell, or Hold?
ORGO - Organogenesis Holdings Inc. Class A Common Stock
$1.80
-0.04 (-2.17%)
▼
5d:
+0.56%
30d:
-25.93%
90d:
-32.33%
HOLD
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When ORGO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ORGO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ORGO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: ORGO is currently trading at $1.80, which is considered oversold relative to its 30-day fair value range of $1.88 to $2.56. From a valuation perspective, the stock is trading at a discount (Forward PE: -5.8) compared to its historical average (18.1). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ORGO is in a downtrend. Immediate support is located at $1.70, while resistance sits at $2.01.
Market Sentiment: ORGO scores 98/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $2.00 (+11.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ORGO is in a downtrend. Immediate support is located at $1.70, while resistance sits at $2.01.
Market Sentiment: ORGO scores 98/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $2.00 (+11.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.88 -
$2.56
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
92.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (98/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($2.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 25% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$1.88 -
$2.56
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.70
Resistance Level
$2.01
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.81
Wall Street Target
$2.00
(+11.1%)
Revenue Growth (YoY)
-56.7%
Earnings Growth (YoY)
555.2%
Profit Margin
-18.4%
PE vs Historical
-5.8 vs 18.1
CHEAP
Share & Embed Analysis
Last updated: August 24, 2026 2:53 AM ET
Data refreshes hourly during market hours. Next update: 3:53 AM
Data refreshes hourly during market hours. Next update: 3:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORGO showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Arthur S Leibowitz
BUY
5000 shares
2026-03-09
Michael Joseph Driscoll
BUY
10000 shares
2026-03-09
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
